Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate

被引:18
|
作者
Moroni, Gabriella [1 ]
Gatto, Mariele [2 ]
Raffiotta, Francesca [1 ]
Binda, Valentina [1 ]
Frangou, Eleni [3 ,4 ]
Lightstone, Liz [5 ]
Boumpas, Dimitrios T. [4 ,6 ,7 ]
机构
[1] Fdn IRCCS Ca Granda Osped Maggiore Milano, Unita Operat Nefrol & Dialisi, Milan, Italy
[2] Univ Padua, Dept Med, Unit Rheumatol, Padua, Italy
[3] Nicosia Gen Hosp, Nicosia, Cyprus
[4] Univ Cyprus, Med Sch, Nicosia, Cyprus
[5] Imperial Coll London, Fac Med, Dept Med, Sect Renal Med & Vasc Inflammat,Imperial Coll Lup, London, England
[6] Univ Athens, Med Sch, Attikon Univ Hosp, Dept Med 4,Joint Rheumatol Program, Athens, Greece
[7] Athens Acad, Biomed Res Fdn, Athens, Greece
关键词
Lupus nephritis; Immunosuppression; Organ damage; Remission; DISEASE-ACTIVITY; PULSE METHYLPREDNISOLONE; PROLONGED REMISSION; INCEPTION COHORT; CONTROLLED-TRIAL; RENAL OUTCOMES; ORGAN DAMAGE; RISK-FACTORS; ERYTHEMATOSUS; THERAPY;
D O I
10.1016/j.autrev.2017.11.003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Lupus nephritis (LN) treatment requires an initial intensive period of therapy followed by a long-term maintenance treatment in order to stabilize disease control and eventually reach renal remission. In this section, Authors discuss the feasibility of safely lowering and even suspending maintenance therapy in LN patients having entered remission, highlighting hurdles in predicting the depth and durability of disease quiescence together with the need for minimizing potentially toxic therapies. Even though no firm conclusions can still be drawn, the treating physician has to find the wise balance between disease control and treatment-related drawbacks by following patients closely and recognizing as early as possible the ones who are likely to reach a deep and durable renal remission; there is consensus that is these are the only patients in whom a potential safe complete withdrawal can be foreseen so far. (C) 2017 Published by Elsevier B.V.
引用
收藏
页码:11 / 18
页数:8
相关论文
共 50 条
  • [1] Can we withdraw immunosuppressants in remitted patients?
    Zen, Margherita
    LUPUS SCIENCE & MEDICINE, 2020, 7 (SUPPL_2): : A8 - A9
  • [2] PROLONGED REMISSION IN PATIENTS WITH LUPUS NEPHRITIS
    Monova, Daniela
    Monov, Simeon
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [3] PROLONGED REMISSION IN PATIENTS WITH LUPUS NEPHRITIS
    Monov, S.
    Monova, D.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 41 - 41
  • [4] Maintenance treatment of proliferative lupus nephritis can be discontinued after remission in some patients
    Cheuk-Chun Szeto
    Lai-Shan Tam
    Nature Clinical Practice Nephrology, 2006, 2 : 672 - 673
  • [5] Maintenance treatment of proliferative lupus nephritis can be discontinued after remission in some patients
    Szeto, Cheuk-Chun
    Tam, Lai-Shan
    NATURE CLINICAL PRACTICE NEPHROLOGY, 2006, 2 (12): : 672 - 673
  • [6] Severe infections in patients with lupus nephritis treated with immunosuppressants: A retrospective cohort study
    Lim, Cynthia C.
    Liu, Pei Yun
    Tan, Hui Zhuan
    Lee, Peishan
    Chin, Yok Mooi
    Mok, Irene Y. J.
    Chan, Choong Meng
    Choo, Jason C. J.
    NEPHROLOGY, 2017, 22 (06) : 478 - 484
  • [7] Silence is golden: Can we predict onset of lupus nephritis?
    Neild, GH
    NEPHRON CLINICAL PRACTICE, 2004, 98 (04): : C101 - C102
  • [8] DO WE KNOW HOW AND WHEN TO STOP IMMUNOSUPPRESSANTS IN LUPUS PATIENTS?
    Touma, Z.
    Gladman, D. D.
    Ibanez, D.
    Urowitz, M. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 76 - 76
  • [9] Kidney Transplantation in Lupus Nephritis: Can We Do Even Better?
    Goyal, Nitender
    Weiner, Daniel E.
    Levey, Andrew S.
    ANNALS OF INTERNAL MEDICINE, 2019, 170 (04) : 266 - +
  • [10] Can we manage lupus nephritis without chronic corticosteroids administration?
    Lightstone, Liz
    Doria, Andrea
    Wilson, Hannah
    Ward, Frank L.
    Larosa, Maddalena
    Bargman, Joanne M.
    AUTOIMMUNITY REVIEWS, 2018, 17 (01) : 4 - 10